Sanofi Total Assets 1999-2025 | SNY
Sanofi total assets from 1999 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Sanofi total assets for the quarter ending June 30, 2025 were $141.854B, a 1.52% increase year-over-year.
- Sanofi total assets for 2024 were $143.701B, a 4.99% increase from 2023.
- Sanofi total assets for 2023 were $136.872B, a 2.51% increase from 2022.
- Sanofi total assets for 2022 were $133.514B, a 6.15% decline from 2021.
Sanofi Annual Total Assets
(Millions of US $) |
| 2024 |
$143,701 |
| 2023 |
$136,872 |
| 2022 |
$133,514 |
| 2021 |
$142,258 |
| 2020 |
$130,827 |
| 2019 |
$126,264 |
| 2018 |
$131,573 |
| 2017 |
$112,833 |
| 2016 |
$115,830 |
| 2015 |
$113,617 |
| 2014 |
$129,463 |
| 2013 |
$127,603 |
| 2012 |
$129,133 |
| 2011 |
$139,510 |
| 2010 |
$113,222 |
| 2009 |
$111,636 |
| 2008 |
$75,778 |
| 2007 |
$98,573 |
| 2006 |
$97,686 |
| 2005 |
$107,924 |
| 2004 |
$95,476 |
| 2003 |
$12,280 |
| 2002 |
$9,918 |
| 2001 |
$8,833 |
| 2000 |
$7,329 |
| 1999 |
$6,855 |
| 1998 |
$7,464 |
Sanofi Quarterly Total Assets
(Millions of US $) |
| 2025-06-30 |
$141,854 |
| 2025-03-31 |
$138,948 |
| 2024-12-31 |
$143,701 |
| 2024-09-30 |
$0 |
| 2024-06-30 |
$139,733 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$136,872 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$136,685 |
| 2023-03-31 |
$0 |
| 2022-12-31 |
$133,514 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$129,647 |
| 2022-03-31 |
$0 |
| 2021-09-30 |
$0 |
| 2021-03-31 |
$0 |
| 2020-09-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-09-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
$112,833 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$112,077 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$115,830 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$111,958 |
| 2016-03-31 |
$0 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$108,322 |
| 2014-06-30 |
$124,450 |
| 2013-06-30 |
$126,655 |
| 2012-06-30 |
$130,750 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$139,510 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$143,306 |
| 2011-03-31 |
$0 |
| 2010-12-31 |
$113,222 |
| 2010-09-30 |
$0 |
| 2010-06-30 |
$110,057 |
| 2010-03-31 |
$0 |
| 2009-12-31 |
$111,636 |
| 2009-09-30 |
$0 |
| 2009-06-30 |
$104,552 |
| 2009-03-31 |
$0 |
| 2008-12-31 |
$105,915 |
| 2008-09-30 |
$0 |
| 2008-06-30 |
$105,535 |
| 2008-03-31 |
$0 |
| 2007-12-31 |
$98,573 |
| 2007-09-30 |
$0 |
| 2007-06-30 |
$101,220 |
| 2007-03-31 |
$0 |
| 2006-12-31 |
$97,686 |
| 2006-09-30 |
$0 |
| 2006-06-30 |
$102,440 |
| 2006-03-31 |
$0 |
| 2005-12-31 |
$107,924 |
| 2005-09-30 |
$0 |
| 2005-06-30 |
$112,588 |
| 2005-03-31 |
$0 |
| 2004-12-31 |
$95,476 |
| 2004-06-30 |
$12,730 |
| 2003-12-31 |
$12,280 |
| 2003-06-30 |
$10,046 |
| 2002-12-31 |
$9,918 |
| 2002-06-30 |
$8,674 |
| 2001-12-31 |
$8,833 |
| 2001-06-30 |
$7,162 |
| 2000-12-31 |
$7,329 |
| 1999-12-31 |
$6,855 |
| 1998-12-31 |
$7,464 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$132.955B |
$45.310B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
